(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 41.35% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Regenxbio's revenue in 2026 is $170,441,000.On average, 14 Wall Street analysts forecast RGNX's revenue for 2026 to be $13,969,054,120, with the lowest RGNX revenue forecast at $6,751,494,437, and the highest RGNX revenue forecast at $21,081,323,315. On average, 10 Wall Street analysts forecast RGNX's revenue for 2027 to be $18,123,899,332, with the lowest RGNX revenue forecast at $8,039,238,388, and the highest RGNX revenue forecast at $26,955,913,154.
In 2028, RGNX is forecast to generate $25,753,846,756 in revenue, with the lowest revenue forecast at $19,240,804,305 and the highest revenue forecast at $32,949,728,986.